773 A Double-Blind Placebo Controlled Study of Acotiamide Hydrochloride for Efficacy on Gastrointestinal Motility of Patients With Functional Dyspepsia

[1]  M. Matsushita,et al.  Emerging treatments in neurogastroenterology: Acotiamade, a novel treatment option for functional dyspepsia , 2016, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

[2]  Chaomin Wan,et al.  Efficacy and Safety of Acotiamide for the Treatment of Functional Dyspepsia: Systematic Review and Meta-Analysis , 2014, TheScientificWorldJournal.

[3]  洋一 齋藤,et al.  新規機能性ディスペプシア（FD）治療薬アコチアミド塩酸塩水和物（アコファイド®錠100 mg）の薬理学的特性と臨床試験成績 , 2014 .

[4]  F. Azpiroz,et al.  Gastric sensitivity and reflexes: basic mechanisms underlying clinical problems , 2014, Journal of Gastroenterology.

[5]  J. Tack,et al.  In functional dyspepsia, hypersensitivity to postprandial distention correlates with meal-related symptom severity. , 2013, Gastroenterology.

[6]  Nicholas J. Talley,et al.  Functional dyspepsia—symptoms, definitions and validity of the Rome III criteria , 2013, Nature Reviews Gastroenterology &Hepatology.

[7]  T. Kashiwagi,et al.  Use of scintigraphy to evaluate gastric accommodation and emptying: Comparison with barostat , 2013, Journal of gastroenterology and hepatology.

[8]  Y-L Zhang,et al.  Relationship between Symptoms and Gastric Emptying of Solids in Functional Dyspepsia , 2012, The Journal of international medical research.

[9]  J. Tack,et al.  Acotiamide, a novel gastroprokinetic for the treatment of patients with functional dyspepsia: postprandial distress syndrome , 2012, Expert review of gastroenterology & hepatology.

[10]  M. Takei,et al.  Acotiamide, a new orally active acetylcholinesterase inhibitor, stimulates gastrointestinal motor activity in conscious dogs , 2012, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

[11]  H. Imamura,et al.  Therapeutic efficacy of acotiamide in patients with functional dyspepsia based on enhanced postprandial gastric accommodation and emptying: randomized controlled study evaluation by real‐time ultrasonography , 2012, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

[12]  M. Hongo,et al.  A placebo-controlled trial of acotiamide for meal-related symptoms of functional dyspepsia , 2011, Gut.

[13]  M. Hongo,et al.  A Long-Term Study of Acotiamide in Patients with Functional Dyspepsia: Results from an Open-Label Phase III Trial in Japan on Efficacy, Safety and Pattern of Administration , 2011, Digestion.

[14]  M. Takei,et al.  Acotiamide hydrochloride (Z-338) enhances gastric motility and emptying by inhibiting acetylcholinesterase activity in rats. , 2011, European journal of pharmacology.

[15]  J. Tack,et al.  Acotiamide (Z-338, YM443), a new drug for the treatment of functional dyspepsia , 2011, Expert opinion on investigational drugs.

[16]  J. Tack,et al.  Acotiamide Hydrochloride (Z-338), a New Selective Acetylcholinesterase Inhibitor, Enhances Gastric Motility without Prolonging QT Interval in Dogs: Comparison with Cisapride, Itopride, and Mosapride , 2011, Journal of Pharmacology and Experimental Therapeutics.

[17]  K. Tominaga,et al.  Prevalence of overlaps between GERD, FD and IBS and impact on health‐related quality of life , 2010, Journal of gastroenterology and hepatology.

[18]  T. Hibi,et al.  Acotiamide (Z‐338) as a possible candidate for the treatment of functional dyspepsia , 2010, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

[19]  M. Hongo,et al.  Clinical trial: dose‐dependent therapeutic efficacy of acotiamide hydrochloride (Z‐338) in patients with functional dyspepsia – 100 mg t.i.d. is an optimal dosage , 2010, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

[20]  M. Vieth,et al.  Anxiety is associated with uninvestigated and functional dyspepsia (Rome III criteria) in a Swedish population-based study. , 2009, Gastroenterology.

[21]  A. Berstad,et al.  A dose‐ranging, placebo‐controlled, pilot trial of Acotiamide in patients with functional dyspepsia , 2009, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

[22]  H. Zai,et al.  Investigation of Gastric Emptying Disorders in Patients with Functional Dyspepsia Reveals Impaired Inhibitory Gastric Emptying Regulation in the Early Postcibal Period , 2009, Digestion.

[23]  J. Tack,et al.  Acotiamide hydrochloride (Z‐338), a novel prokinetic agent, restores delayed gastric emptying and feeding inhibition induced by restraint stress in rats , 2008, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

[24]  J. Tack,et al.  Pathogenesis of Dyspepsia , 2008, Digestive Diseases.

[25]  M. Camilleri,et al.  Consensus Recommendations for Gastric Emptying Scintigraphy: A Joint Report of the American Neurogastroenterology and Motility Society and the Society of Nuclear Medicine , 2008, The American Journal of Gastroenterology.

[26]  K. Tominaga,et al.  Concurrent assessment of reservoir and emptying of the stomach for dyspepsia patients. , 2008, Hepato-gastroenterology.

[27]  J. Matiasek,et al.  Hypersensitivity for capsaicin in patients with functional dyspepsia , 2007, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

[28]  J. Tack,et al.  Impaired gastric accommodation and its role in dyspepsia , 2006, Gut.

[29]  P. Moayyedi,et al.  American gastroenterological association technical review on the evaluation of dyspepsia. , 2005, Gastroenterology.

[30]  R. Bisschops,et al.  Mechanisms underlying meal-induced symptoms in functional dyspepsia. , 2004, Gastroenterology.

[31]  J. Tack,et al.  Pathophysiology of functional dyspepsia. , 2004, Best practice & research. Clinical gastroenterology.

[32]  J. Ware,et al.  Usefulness of the SF-8™ Health Survey for comparing the impact of migraine and other conditions , 2003, Quality of Life Research.

[33]  Peter Henningsen,et al.  Medically Unexplained Physical Symptoms, Anxiety, and Depression: A Meta‐Analytic Review , 2003, Psychosomatic medicine.

[34]  M. Camilleri,et al.  Functional gastroduodenal disorders , 1999, Gut.

[35]  A. Hoes,et al.  Disturbed Solid-Phase Gastric Emptying in Functional Dyspepsia (A Meta-Analysis) , 1998, Digestive Diseases and Sciences.

[36]  D. Thompson,et al.  Evaluation of gastric antral motor performance in patients with dysmotility‐like dyspepsia using real‐time high‐resolution ultrasound , 1996, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

[37]  O. H. Gilja,et al.  Impaired accommodation of proximal stomach to a meal in functional dyspepsia , 1996, Digestive Diseases and Sciences.

[38]  I. Wiklund,et al.  Quality of life in patients with upper gastrointestinal symptoms. An improved evaluation of treatment regimens? , 1993, Scandinavian journal of gastroenterology.

[39]  R. Snaith,et al.  The Hospital Anxiety And Depression Scale , 2003, Health and quality of life outcomes.

[40]  R. Farré,et al.  Changes in gastrointestinal tract function and structure in functional dyspepsia , 2013, Nature Reviews Gastroenterology &Hepatology.

[41]  Sachie K. Ogawa,et al.  Effects of Z-338, a novel gastroprokinetic agent, on the actions of excitatory and inhibitory neurotransmitters on neurons in area postrema. , 2010, Journal of smooth muscle research = Nihon Heikatsukin Gakkai kikanshi.